January 19, 2018
Otsuka Pharmaceutical Co., Ltd.
Otsuka Receives Approval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
Otsuka Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets® (generic name is brexpiprazole) in 1mg and 2 mg dosage sizes.
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.
Information in this news release was current as of the original release date.